The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
暂无分享,去创建一个
F. Breedveld | P. Emery | F. Breedveld | J. Kalden | C. Deighton | H. Sörensen | M. Schattenkirchner | B. Rozman | P Emery | J R Kalden | H Sörensen | M Schattenkirchner | F Breedveld | B Rozman | C Deighton
[1] O. Steinbrocker,et al. Therapeutic criteria in rheumatoid arthritis. , 1949, Journal of the American Medical Association.
[2] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.
[3] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[4] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[5] T. Pincus,et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. , 1992, The Journal of rheumatology.
[6] P. Tugwell,et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. , 1993, The Journal of rheumatology.
[7] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[8] H. Simmonds,et al. Importance of Ribonucleotide Availability to Proliferating T-lymphocytes from Healthy Humans , 1995, The Journal of Biological Chemistry.
[9] J. Fries,et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. , 1996, Arthritis and rheumatism.
[10] Jack Parker Davis,et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. , 1996, Biochemistry.
[11] F. Wolfe. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. , 1997, Clinical and experimental rheumatology.
[12] G. Wahl,et al. Mechanism of action for leflunomide in rheumatoid arthritis. , 1999, Clinical immunology.
[13] J. Smolen,et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial , 1999, The Lancet.
[14] V. Strand,et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. , 1999, Archives of internal medicine.
[15] Dayer Jm,et al. Leflunomide: mode of action in the treatment of rheumatoid arthritis , 2000, Annals of the rheumatic diseases.
[16] R. Dahl,et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. , 2000, Rheumatology.
[17] S Gallivan,et al. Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies. , 2000, Rheumatology.
[18] V. Strand,et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. , 2001, Arthritis and rheumatism.
[19] David Steven Scott,et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine , 2001, Annals of the rheumatic diseases.
[20] Pamela F. Jones,et al. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. , 2001, The Journal of rheumatology.
[21] R. Rau,et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. , 2001, Scandinavian journal of rheumatology.
[22] Michael Weisman,et al. Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate , 2002, Annals of Internal Medicine.
[23] R. Schleyerbach,et al. Effects of leflunomide on immune responses and models of inflammation , 2004, Springer Seminars in Immunopathology.